Skip to content
PubMed This is a summary of 49 peer-reviewed journal articles Updated
Hematology

Aceruloplasminemia: A Patient Guide

At a Glance

Aceruloplasminemia is a CP gene disorder that traps iron in organs while leaving too little usable iron in the blood. Early specialist monitoring and individualized chelation may protect organs and delay neurological problems, but treatment must be balanced against anemia.

Aceruloplasminemia is a rare genetic condition that fundamentally changes how your body manages iron. Typically, your body uses a protein called ceruloplasmin to act as a ferroxidase, helping to oxidize iron so it can be exported from storage cells and move through the blood to build healthy red blood cells [1][2]. Because of a mutation in the CP gene, your body cannot produce this functional protein, leading to a strange and challenging biological paradox: your organs become overloaded with trapped iron because iron mobilization is impaired, while your blood remains functionally starved for it [3][4].

This iron imbalance often follows a slow but predictable timeline as the metal gradually builds up in different tissues, though not everyone develops every symptom. For many, the first sign is a form of microcytic anemia (small red blood cells) that appears in early adulthood, which can feel like persistent fatigue [5][1]. As iron continues to accumulate in the pancreas, many patients develop diabetes, often in their 30s or 40s [6]. If left unmanaged, the iron may eventually reach the brain and the back of the eyes, leading to neurological changes like balance issues, tremors, or involuntary movements later in life [7][8].

The most important takeaway for living with aceruloplasminemia is that early intervention matters. Because there is often a decade or more between the first signs of anemia and the onset of neurological symptoms, there is a “window of opportunity” for treatment [6][1]. Starting iron-reduction therapy, such as chelation, before neurological symptoms appear may reduce or delay disease progression in some reported cases, though treatment decisions must be highly individualized [9]. While these treatments must be carefully balanced to avoid worsening your anemia, they are the primary tool your medical team uses to protect your organs from the effects of iron overload [10][9]. Due to the risks, never take iron supplements or undergo phlebotomy without direct specialist confirmation.

Living with this condition requires a dedicated partnership with a team of specialists who understand its complexity. By monitoring your blood work, eye health, and organ iron levels regularly, you and your doctors can make informed adjustments to your care. While the diagnosis is life-changing, understanding the underlying biology of the iron paradox empowers you to take proactive steps in managing your long-term health and maintaining your quality of life.

Common questions in this guide

What causes aceruloplasminemia?
A mutation in the CP gene prevents the body from making functional ceruloplasmin, a protein that helps release stored iron so it can travel in the blood. Without this function, iron can build up in organs while the blood has too little usable iron.
How can aceruloplasminemia cause both iron overload and anemia?
The condition impairs the movement of iron out of storage cells and into the bloodstream. This can leave iron trapped in organs while there is not enough usable iron in the blood to support normal red blood cell production.
What symptoms may appear first, and what can happen later?
Microcytic anemia, which means unusually small red blood cells, is often an early sign and may cause persistent fatigue. Diabetes can develop as iron accumulates in the pancreas, while later brain involvement may cause balance problems, tremors, or involuntary movements; not everyone develops every symptom.
Can chelation treatment slow aceruloplasminemia?
Chelation is the main iron-reduction treatment discussed for aceruloplasminemia. Starting it before neurological symptoms appear may reduce or delay progression in some people, but the treatment plan must be individualized because removing iron can worsen anemia.
How will doctors monitor aceruloplasminemia over time?
Monitoring may include regular blood tests, checks of iron levels in organs, and eye-health assessments. Specialists use these results to adjust care while watching for worsening anemia and changes in organ involvement.
Should I take iron supplements or have phlebotomy for aceruloplasminemia?
Do not take iron supplements or undergo phlebotomy, a blood-removal procedure, unless a specialist familiar with aceruloplasminemia specifically recommends it. Iron can be trapped in organs even when anemia is present, so these approaches require careful medical review.
Which specialists may be involved in aceruloplasminemia care?
A multidisciplinary team may be helpful because aceruloplasminemia can affect the blood, pancreas, brain, and eyes. The page specifically highlights hematology and neurology expertise, with additional specialists considered according to the organs and symptoms involved.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the specific status of my iron distribution: how high is the iron in my organs compared to how little is in my blood?
  2. 2.Based on my age and current labs, where am I on the typical timeline for anemia and diabetes?
  3. 3.What are the immediate goals for my iron chelation therapy—is it to remove iron from my organs or to stabilize my current blood counts?
  4. 4.How will we monitor my progress to ensure my anemia doesn't become severe while we are removing iron?
  5. 5.Given the rarity of this condition, how can we connect with a multidisciplinary team that includes experts in both hematology and neurology?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (10)
  1. 1

    Aceruloplasminemia: Waiting for an Efficient Therapy.

    Piperno A, Alessio M

    Frontiers in neuroscience 2018; (12()):903 doi:10.3389/fnins.2018.00903.

    PMID: 30568573
  2. 2

    Does Ceruloplasmin Defend Against Neurodegenerative Diseases?

    Wang B, Wang XP

    Current neuropharmacology 2019; (17(6)):539-549 doi:10.2174/1570159X16666180508113025.

    PMID: 29737252
  3. 3

    Ceruloplasmin deficiency does not induce macrophagic iron overload: lessons from a new rat model of hereditary aceruloplasminemia.

    Kenawi M, Rouger E, Island ML, et al.

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2019; (33(12)):13492-13502 doi:10.1096/fj.201901106R.

    PMID: 31560858
  4. 4

    Genetic and Clinical Heterogeneity in Thirteen New Cases with Aceruloplasminemia. Atypical Anemia as a Clue for an Early Diagnosis.

    Vila Cuenca M, Marchi G, Barqué A, et al.

    International journal of molecular sciences 2020; (21(7)) doi:10.3390/ijms21072374.

    PMID: 32235485
  5. 5

    A novel ceruloplasmin mutation identified in a Chinese patient and clinical spectrum of aceruloplasminemia patients.

    Xu WQ, Ni W, Wang RM, et al.

    Metabolic brain disease 2021; (36(8)):2273-2281 doi:10.1007/s11011-021-00799-0.

    PMID: 34347207
  6. 6

    Aceruloplasminemia presents as Type 1 diabetes in non-obese adults: a detailed case series.

    Vroegindeweij LH, van der Beek EH, Boon AJ, et al.

    Diabetic medicine : a journal of the British Diabetic Association 2015; (32(8)):993-1000 doi:10.1111/dme.12712.

    PMID: 25661792
  7. 7

    New insights in the neurological phenotype of aceruloplasminemia in Caucasian patients.

    Vroegindeweij LHP, Langendonk JG, Langeveld M, et al.

    Parkinsonism & related disorders 2017; (36()):33-40 doi:10.1016/j.parkreldis.2016.12.010.

    PMID: 28012953
  8. 8

    [Aceruloplasminemia, a rare condition not to be overlooked].

    Lobbes H, Reynaud Q, Mainbourg S, et al.

    La Revue de medecine interne 2020; (41(11)):769-775 doi:10.1016/j.revmed.2020.06.002.

    PMID: 32682623
  9. 9

    Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports.

    Vroegindeweij LHP, Boon AJW, Wilson JHP, Langendonk JG

    Orphanet journal of rare diseases 2020; (15(1)):105 doi:10.1186/s13023-020-01385-w.

    PMID: 32334607
  10. 10

    Phenotypic heterogeneity in seven Italian cases of aceruloplasminemia.

    Pelucchi S, Mariani R, Ravasi G, et al.

    Parkinsonism & related disorders 2018; (51()):36-42 doi:10.1016/j.parkreldis.2018.02.036.

    PMID: 29503155

This page is for informational purposes only and does not constitute medical advice. Because iron-reduction treatment can worsen anemia, consult your specialist before taking iron supplements, starting or changing chelation, or undergoing phlebotomy.

Get notified when new evidence is published on Aceruloplasminemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.